Skip to main content
. Author manuscript; available in PMC: 2023 Apr 14.
Published in final edited form as: Alzheimers Dement. 2022 Aug 7;19(4):1175–1183. doi: 10.1002/alz.12754

Figure 5. False positive participants enrolled via approach D.

Figure 5.

The number and proportion of individuals enrolled via approach D with a positive AD blood test who would be expected to have a negative amyloid PET scan (“false positives”) as a function of the specificity of the AD blood test for brain amyloidosis, stratified by the sensitivity (A). The number and percent of false positives as a function of the sensitivity stratified by the specificity (B). The number of individuals who must be called to yield 100 amyloid PET positive individuals who meet study criteria as a function of the AD blood test sensitivity (C), assuming that 75% of individuals called are eligible for the study.